Tests umbilical cord stem cells for stroke recovery
Tests umbilical cord stem cells against placebo in adults with ischemic stroke.
Plain-language title generated from the registry record
Registry title: Clinical Trial of Umbilical Cord Mesenchymal Stem Cells in Subacute Ischemic Stroke
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults 18 to 70 years old who had an ischemic stroke in the front part of the brain 14 to 90 days ago and are in the recovery phase.
- Age
- 18 to 70 years
- Sex
- All sexes can join.
- Disease stage
- Ischemic stroke in the anterior circulation, 14 to 90 days after the stroke (recovery phase). NIHSS score of 6-20 points, with arm or leg motor score of 2-4 points and level of consciousness item (1a) score below 2.
Main reasons for not taking part
- History of epilepsy, dementia, Parkinson's disease, severe depression, or other neurological or psychiatric disorders
- Bleeding inside the skull (intracranial hemorrhage)
- Pre-stroke mRS score above 1
- Severe cardiovascular disease
- Severe lung disease
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07197606, who can take part
Where in China
- Xuanwu Hospital, Capital Medical UniversityBeijing, ChinaContact: Gaoting Ma, MDNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Shanghai IxCell Biotechnology Co., LTD
- Trial code
- NCT07197606
- Record updated
- 29 September 2025
- Original description
The goal of this clinical trial is to evaluate the efficacy, safety, and pharmacodynamic characteristics of Human Umbilical Cord Mesenchymal Stem Cells (hUC-MSCs) in adults with ischemic stroke in the anterior circulation during the recovery phase. Researchers will compare hUC-MSCs to a placebo to determine whether hUC-MSCs treatment is effective in treating recovery-phase anterior circulation ischemic stroke.Read full original descriptionShow less
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase II Clinical Study to Evaluate the Efficacy and Safety of IxCell hUC-MSC-S in Patients With Ischemic Stroke in the Recovery Phase
The goal of this clinical trial is to evaluate the efficacy, safety, and pharmacodynamic characteristics of Human Umbilical Cord Mesenchymal Stem Cells (hUC-MSCs) in adults with ischemic stroke in the anterior circulation during the recovery phase. Researchers will compare hUC-MSCs to a placebo to determine whether hUC-MSCs treatment is effective in treating recovery-phase anterior circulation ischemic stroke.
Inclusion: Age ≥18 years and ≤70 years, regardless of gender; 14 to 90 days after ischemic stroke; Clinical diagnosis of anterior circulation ischemic stroke; National Institutes of Health Stroke Scale (NIHSS) score is 6-20 points (inclusive), with NIHSS motor arm (item 5) or motor leg (item 6) score of 2-4 points, and NIHSS level of consciousness item (1a) score <2 points; It was anticipated that participants would either be able to give informed consent or have a legal representative who could do so.
Exclusion: People who had a history of epilepsy, dementia, Parkinson's disease, severe depression, or other neurological or psychiatric disorders; Intracranial hemorrhagic conditions; Pre-stroke mRS score >1; Severe cardiovascular disease; Severe pulmonary diseases.